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Translation initiation activationIn eukaryotic protein synthesis the translation initiation factor 3 (eIF3) is a key player in the recruitment and
assembly of the translation initiation machinery. Mammalian eIF3 consists of 13 subunits, including the loosely
associated eIF3j subunit that plays a stabilizing role in the eIF3 complex formation and interaction with the
40S ribosomal subunit. By means of both co-immunoprecipitation and mass spectrometry analyses we demon-
strate that the protein kinase CK2 interacts with and phosphorylates eIF3j at Ser127. Inhibition of CK2 activity
by CX-4945 or down-regulation of the expression of CK2 catalytic subunit by siRNA cause the dissociation of
j-subunit from the eIF3 complex as judged from glycerol gradient sedimentation. This ﬁnding proves that CK2-
phosphorylation of eIF3j is a prerequisite for its association with the eIF3 complex. Expression of Ser127Ala-
eIF3j mutant impairs both the interaction of mutated j-subunit with the other eIF3 subunits and the overall
protein synthesis. Taken together our data demonstrate that CK2-phosphorylation of eIF3j at Ser127 promotes
the assembly of the eIF3 complex, a crucial step in the activation of the translation initiation machinery.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
In eukaryotic protein synthesis, initiation of translation is a complex
sequence of reactions requiring the interaction of the ribosome with a
number of eukaryotic translation initiation factors (eIFs). A key player
in the recruitment and assembly of the translation initiation machinery
is the multiprotein complex eIF3, which stimulates many steps of the
pathway. These include assembly of the eIF2-GTP/met-tRNAi complex
and of other eIFs to the 40S ribosomal subunit to form the 43S
preinitiation complex, recruitment of mRNA to the 43S complex,
prevention of the 40S ribosome from joining the 60S prematurely, and
the scanning of mRNA for AUG recognition [reviewed in 1,2]. In
mammals, eIF3 contains 13 different subunits, which are named IF3a
to eIF3m in order of decreasing molecular weight, and possesses an an-
thropomorphic ﬁve-lobed structure [3] organized around a functional
core complex [4,5]. Structural analysis suggests that eIF3 performs a
scaffolding function by binding to the 40S subunit on its solvent-
exposed surface rather than on its interface with the 60S subunit,Sciences, University of Padova,
110; fax: +39 049 8276363.
Deana).where the decoding sites are located [3]. This location of eIF3 seems
ideally suited for its other proposed regulatory functions, including its
acting as a receptor for protein kinases that control protein synthesis
[6,7]. eIF3j is a nonstoichiometric and highly conserved subunit, that is
loosely associated with the eIF3 complex [8,9]. It makes multiple inde-
pendent interactions with the eIF3 core [5] and its binding to the
eIF3b N-terminal RNA recognition motif plays a stabilizing role in
forming the eIF3 complex [10]. eIF3j is required for high-afﬁnity binding
of eIF3 to the 40S ribosomal subunit, it associates with the decoding
center of the 40S subunit and governs the binding of initiation factors
and mRNA to form a scanning-competent initiation complex [8,9,
11–13]. It has been also proposed that eIF3j promotes mRNA dissocia-
tion during the ribosomal recycling step [14].
Protein kinase CK2 is a ubiquitous, highly conserved and pleiotropic
Ser/Thr kinase, endowed with constitutive activity, independent of any
known second messenger or phosphorylation events. The kinase is
usually present as a tetrameric holoenzyme composed of two catalytic
subunits (α and/or α′) and two non-catalytic β-subunits. CK2
phosphorylates a huge number of protein substrates, implicated in fun-
damental cell processes. Among the CK2 substrates there are also tran-
scription factors, modulators of DNA and RNA structure, and proteins
involved in RNA and protein biosynthesis, which highlight the
1694 C. Borgo et al. / Biochimica et Biophysica Acta 1853 (2015) 1693–1701importance of CK2 in controlling gene expression [15,16]. CK2 is abnor-
mally elevated in awide variety of tumors, where it plays a global role as
an anti-apoptotic and pro-survival agent operating as a cancer driver by
creating a cellular environment favorable to neoplasia [17–19].
In this studywe show that the protein kinase CK2 interacts with and
phosphorylates the j subunit of the eIF3 complex. CK2-catalyzed phos-
phorylation of eIF3j triggers the association of this subunit with eIF3
complex promoting an efﬁcient translation initiation.2. Materials and methods
2.1. Materials and antibodies
[γ-33P]ATP was purchased from Hartmann Analytic GmbH (Braun-
schweig Germany). Protease inhibitor cocktail was from Calbiochem
(Darmstadt, Germany), while phosphatase inhibitor cocktails 2 and 3
and the kit for molecular weight markers were from Sigma-Aldrich
(Dorset, UK). CX-4945 was purchased from AbMole BioScience
(Hong Kong, China), staurosporine from Sigma-Aldrich (Dorset, UK)
and quinalizarin was kindly provided by Dr. G. Cozza, University of Pa-
dova, Italy [20]. RRRADDSDDDDD peptide [21] and recombinant CK2
(α2β2) [22] were kindly provided by Dr. Oriano Marin and Dr. Andrea
Venerando (University of Padova, Italy), respectively. Antiserumagainst
CK2α subunit was raised in rabbit using the peptide reproducing the se-
quence of the human catalytic subunit at the C-terminus (376–391).
The peptide was coupled to keyhole limpet hemocyanin using
m-maleimidobenzoyl-N-hydroxysuccinimide ester (Fischer Scientiﬁc,
IllkirchCedex, France). Anti-CK2β antibodywas fromEpitomics (Burlin-
game, CA), while antibodies raised against Fyn, eIF3j, eIF3b, eIF3c, eIF3d,
and rpS6 were from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-
Akt1 (phospho-129) was from Abcam (Cambridge, UK), anti-Akt1
from Cell Signaling Technology (Danvers, MA), while anti-β-actin and
anti-c-Myc were purchased from Sigma-Aldrich.2.2. Cell culture
HEK293 (human embryonic kidney) and Hela (cervical cancer) cells
were grown in DMEM, while LAMA84 (chronic myeloid leukemia) cells
were maintained in RPMI 1640. Both media were supplemented with
10% fetal calf serum, 2 mM L-glutamine, 100 U/ml penicillin and
100 mg/ml streptomycin.2.3. Cell lysis and western blot analysis
Cells were lysed by suspension (1 h at 4 °C) in the lysis buffer con-
taining 20 mM Tris–HCl (pH 7.5), 1% Triton X-100, 10% glycerol, 1 mM
EDTA, 150 mM NaCl and protease and phosphatase inhibitor cocktails.
After centrifugation (16,000 × g for 15 min) protein concentration
was determined in the supernatants by Bradford method. Proteins
were subjected to 11% SDS-PAGE, blotted on Immobilon-P membranes
(Sigma-Aldrich), processed in western blot with the indicated antibod-
ies and developed using an enhanced chemiluminescent detection
system (ECL). Immunostained bands were quantiﬁed by means of a
Kodak-Image-Station 4000MM-PRO and analysis with Carestream
Molecular Imaging software (New Haven, CT).2.4. Immunoprecipitation experiments
Proteins from cell lysates (400 μg in 250ml) were immunoprecipitated
overnight with the speciﬁc antibody, followed by addition of protein
A-Sepharose for 30min. The immunocomplexes, washed three times
with 0.9 ml of 50 mM Tris–HCl, pH 7.5, were analyzed by western-
blot or tested for CK2 activity by in vitro phosphorylation assay.2.5. Phosphorylation assay of immunoprecipitates
Anti-CK2α, anti-eIF3j and anti-Myc immunoprecipitateswere phos-
phorylated in 25 μl of a phosphorylation medium containing 50 mM
Tris–HCl (pH 7.5), 10 mMMgCl2, 100 mM NaCl and 20 μM [γ-33P]ATP
(about 1000 c.p.m./pmol). Samples were subjected to SDS-PAGE and
blotted. Radioactive proteins were evidenced by a Cyclone Storage
Phosphor-Screen (PerkinElmer, Waltham, MA).
2.6. Identiﬁcation of the eIF3j site phosphorylated by CK2
HEK293 cells, treated with vehicle or CX-4945 were
immunoprecipitated with eIF3j antibody. Immunocomplexes were
loaded on SDS-PAGE and the bands corresponding to the MW of about
35–38 kDa were excised from the gel and digested by trypsin (for
details see Supplementary Materials and Methods). The resulting pep-
tides were subjected to a phosphopeptide enrichment step. Samples
were dried under vacuum and dissolved in 30 μl of a loading buffer
that was constituted of 80% acetonitrile (ACN) and 6% triﬂuoroacetic
acid (TFA, riedel-de Haen). Samples were slowly loaded onto home-
made TiO2 micro-columns (prepared as described in [23]) pre-
conditioned twicewith 20 μl of ACNand twicewith 20 μl of loading buff-
er. Micro-columns were then washed twice with 20 μl of loading buffer
and twice with 0.1% TFA (20 μl each time) to increase the pH.
Phosphopeptides bound to the stationary phase were ﬁnally eluted
with 20 μl of freshly prepared NH4OH (5%, pH ≈ 11), and released
from the C18 frit with a further elution step using 50% ACN, 0.1% formic
acid (FA). 2 μl of pure FA was ﬁnally added to acidify the samples.
Phosphopeptides were dried under vacuum and dissolved in 0.1% FA
for mass spectrometry (MS) analysis that was conducted as described
in [24].
Datawere analyzedwith ProteomeDiscoverer software (version 1.4,
Thermo Fisher Scientiﬁc) coupled to a Mascot search engine (version
2.2.4,Matrix Science) against thehuman section of theUniprot database
(release 20140416, 88708 entries). (For further details see the Supple-
mentary Materials and Methods.) The MS/MS spectra of identiﬁed
phosphopeptides were manually inspected for conﬁrmation.
2.7. Glycerol gradient sedimentation
Cells (10 × 106) were lysed with the lysis buffer described in
Section 2.3 containing 0.2% Triton X-100 and 10 mM KCl (instead of
1% Triton X-100 and 150 mM NaCl, respectively). Lysates (300 μl
containing 400 μg of proteins) were layered on the top of a 3.6 ml of a
glycerol discontinuous gradient (0.9 ml of 40%, 0.9 ml of 30%, 0.9 ml of
20% and 0.9 ml of 10%) in 50 mM Hepes, pH 8.0, 1 mM EDTA, 1 mM
DTT, protease and phosphatase inhibitors. The tubes were centrifuged
in a Beckman SW60Ti rotor at 100,000 × g for 18 h at 4 °C and fraction-
ated from the bottom into 19 fractions. Fractions (40 μl) were analyzed
by western blot.
2.8. RNA interference
HEK293 cells (5 × 105) were transfected for 72 h with 30 nM CK2α
and CK2β speciﬁc siGENOME SMARTpool siRNAs (Dharmacon,
Lafayette, CO, USA) or non-speciﬁc siRNA siCONTROL riscfree#1
(Dharmacon). Transfection was performed using the transfecting re-
agent INTERFERin (Polyplus-transfection SA, Illkirch, France) according
to the manufacturer's recommendations.
2.9. CK2 kinase activity assay
Proteins from cell lysates were incubated for 10min at 30 °C in 25 μl
of a phosphorylation medium containing 50 mM Tris–HCl (pH 7.5),
100 mM NaCl, 12 mM MgCl2, 400 μM synthetic peptide-substrate
RRRADDSDDDDD and 20 μM [γ-33P]ATP (1000 cpm/pmol). Assays
Fig. 1. Identiﬁcation of eIF3j as interactor and substrate of CK2. (A) HEK293, Hela and
LAMA84 cells were lysed and lysate proteins were immunoprecipitated (IP) with anti-
CK2α antibody. Immunocomplexes were then phosphorylated in the presence of
[γ-33P]ATP as described in Section 2.5. Vehicle (DMSO), CX-4945 (0.5 μM) or
staurosporine (5 μM) were added to the phosphorylation medium as indicated. After
15 min, samples were loaded on SDS-PAGE and blotted. 33P-radiolabeled proteins were
visualized by a Cyclone Storage Phosphor-Screen. Arrows indicate the position of a radio-
active protein of about 35–38 kDa and of CK2 β-subunit. (B) HEK293 cells were lysed and
lysate proteins were immunoprecipitated with anti-Fyn antibody of the same class (Ctrl)
or anti-eIF3j antibody. (Left panel) Immunocomplexes were loaded on SDS/PAGE and
then analyzed by western blot (Wb) with anti-eIF3j antibody. (Middle and right panels)
In parallel experiments, control and eIF3-immunoprecipitates were loaded on two other
gels together with 50 ng of recombinant CK2 holoenzyme (α2β2). One gel was immuno-
stained with anti-CK2α antibody (middle panel) and the other with anti-CK2β antibody
(right panel). (C) Lysate proteins were immunoprecipitated with anti-eIF3j antibody
and immunocomplexes were phosphorylated in the presence of [γ-33P]ATP. Vehicle or
0.5 μM CX-4945 were added to the phosphorylation medium as indicated. After 15 min,
samples were loaded on SDS-PAGE and blotted. Membranes were analyzed by western
blot (upper panel) or by a Cyclone Storage Phosphor-Screen to visualize the 33P-
radiolabeled eIF3j (lower panel). Figures are representative of four different experiments.
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washed four times in 75 mM phosphoric acid [21] and analyzed by a
Scintillation Counter (PerkinElmer).
2.10. Plasmids and cell transfection
pCMV-Myc vector, pCMV-Myc-wild type eIF3j and pCMV-Myc-
S127A-eIF3j were purchased from GenScript (Piscataway, NJ, USA).
HEK293 cells (1 × 106) were transfected for 96 h with 4.5 μg of the
indicated constructs, using TransIT-LT1 (Mirus Bio LLC, Madison, WI,
USA) according to the protocol recommended by the manufacturer.
2.11. 35S-methionine/cysteine metabolic labeling
HEK293 cells were transfected as described in Section 2.10 and then
cycloheximide (100 μg/ml)was added to a cellmedium for 1 h. Then the
medium was replaced by Met/Cys-free DMEM (Sigma-Aldrich) supple-
mentedwith 2mML-glutamine and 100 μg/ml cycloheximide. After 1 h,
the medium was replaced by Met/Cys-free DMEM supplemented with
2 mM L-glutamine and 10 μCi/ml [35S]-L-Met/Cys Protein Labeling Mix
(Hartmann Analytic GmbH). After 1 h, radiolabeled medium was re-
moved and cells were washed and lysed as described in Section 2.3.
Similar amounts of radioactive lysates were subjected to SDS-PAGE,
blotted and the total labeling was measured using the Cyclone Plus
Storage PhosphorSystem.
2.12. Statistical analysis
Data are presented as means + SD and mean differences were ana-
lyzed using t-test. A p b 0.05 was considered as statistically signiﬁcant.
3. Results
3.1. j-Subunit of eIF3 is a new interactor and substrate of CK2
HEK293, Hela and LAMA84 cells were analyzed in experiments
aimed at identifying new CK2 substrates. Cellular lysates were
immunoprecipitated with an antiserum raised against the human
CK2α C-terminus. Immunocomplexes were then phosphorylated in a
medium containing [γ-33P]ATP. Fig. 1A shows that different co-
immunoprecipitated proteins are 33P-phosphorylated including the
expected CK2 regulatory β-subunit (lanes 1,4,7). The strong inhibition
of the 33P-phosphorylation induced by in vitro addition of the CK2 selec-
tive and potent inhibitor CX-4945 [25] demonstrates that most proteins
are speciﬁcally phosphorylated by the constitutively active CK2 (lanes
2,5,8). Consistently, addition of staurosporine at a concentration ineffec-
tive toward CK2 but able to inhibit most protein kinases [26] does not
affect the protein phosphorylation extent (Fig. 1A, lanes 3,6,9). The ra-
dioactive protein displaying a MW of about 35–38 kDa, which is highly
phosphorylated and present in all the analyzed immunoprecipitates,
was excised from the gel, digested by trypsin and analyzed by mass
spectrometry. The analysis showed that, among the identiﬁed proteins,
the j-subunit of the eukaryotic translation initiation factor 3 (eIF3j)
(MW=29,159) displayed the highest mascot score (see Supplementa-
ry Materials and Methods and Supplementary Table 1). The occurrence
of an interaction between CK2 and eIF3j was further supported by the
presence of CK2α and CK2β subunits in eIF3j-immunoprecipitates
obtained from HEK293 cell lysates (Fig. 1B). The recognition of the
co-immunoprecipitated CK2 subunits was conﬁrmed by running re-
combinant CK2 holoenzyme (α2β2) in parallel with the eIF3j-
immunoprecipitates. The identiﬁcation of eIF3j as a new substrate of
CK2 was strengthened by in vitro phosphorylation experiments per-
formed with eIF3j-immunoprecipitates showing that j-subunit is phos-
phorylated by its interactor CK2. The kinase co-immunoprecipitated
with eIF3j (upper panel of Fig. 1C) speciﬁcally phosphorylates the
subunit as demonstrated by the strong reduction of the eIF3j 33P-phosphorylation caused by in vitro addition of the CK2 inhibitor CX-
4945 (lower panel of Fig. 1C).
The ﬁnding that all the other eIF3 subunits were identiﬁed by mass
spectrometry analysis among the proteins co-immunoprecipitated with
CK2α (see Supplementary Materials and Methods and Supplementary
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complex.
3.2. CK2 phosphorylates eIF3j at Ser127
To check if eIF3j is phosphorylated by CK2 inside the cell, HEK293
cells were treatedwith vehicle or CX-4945 for 5 h and then lysed. Lysate
proteins were immunoprecipitated with anti-eIF3j antibody and the
immunocomplexes were subjected to SDS-PAGE. Protein bands corre-
sponding to j-subunit were excised and digestedwith trypsin. Resulting
phoshopeptides were enriched using TiO2 microcolumns and analyzed
by tandem mass spectrometry, as described in Section 2.6. Fig. 2
shows the extracted ion chromatograms for several identiﬁed peptides
belonging to eIF3j. The eIF3j phosphopeptide LQEEpSDLELAK was
identiﬁed in the control sample (panel A) but not in the sample
immunoprecipitated from cells treated with the CK2 inhibitor CX-
4945 (panel B). The ion at m/z = 677.8087 is indeed detectable only
in the control experiment, and it is absent in the sample derived from
cells treatedwith CX-4945, while all other ions are present in both sam-
ples with similar intensities. The MS/MS spectrum of the ion at m/z =
677.8087 (Fig. 2C) conﬁrms the identiﬁcation of the eIF3j trypticFig. 2. Identiﬁcation of the eIF3j residue phosphorylated by CK2. (A,B) HEK293 cells, trea
immunoprecipitated with anti-eIF3j antibody. Immunocomplexes were loaded on SDS-PAGE a
were excised from the gel and processed for mass spectrometry analysis as described in Secti
MS/MS. Peptides were obtained from the trypsin digestion of eIF3j that was immunoprecipitat
to the phosphopeptide LQEEpSDLELAK. (B) Extracted Ion Chromatograms of the same peptides
case, the signal at m/z= 677.8087 is not present. (C) AnnotatedMS/MS spectrum of ion at m/zphosphopeptide LQEEpSDLELAK containing the residue Ser127, which
is located in a sequence matching the CK2 consensus, which is S/T-X-
X-Acidic residue [16,27].3.3. Inhibition of CK2 increases its binding to eIF3j
Next we assessed whether the inhibition of CK2 activity might affect
the interaction occurring between the kinase and eIF3j. To this purpose,
HEK293 cells were untreated or treated with CX-4945 or quinalizarin
(Q1), two structurally unrelated CK2 inhibitors. Western blot analysis
of cellular lysates demonstrates that CX-4945 and Q1 strongly reduce
the phosphorylation extent of Akt1 Ser129, a speciﬁc target of CK2
[28] (about 80% and 65%, respectively), while they do not change the
protein-level of CK2α, CK2β and eIF3j (Fig. 3A). Cellular lysates were
then immunoprecipitated with anti-CK2α antibody. Interestingly,
while cell treatment with CX-4945 or quinalizarin does not affect the
interaction of the kinase with the eIF3 subunits eIF3b and eIF3d, it
causes an about 3-fold increase of eIF3j co-immunoprecipitation
(Fig. 3B). This ﬁnding is conﬁrmed by eIF3j-immunoprecipitates show-
ing a great enhancement of CK2α and CK2β co-immunoprecipitation inted with vehicle (A) or with 3 μM CX-4945 (B) for 5 h were lysed and lysates were
nd the gel was stained by colloidal “blue silver”. Bands corresponding to the MW of eIF3j
on 2.6. (A) Extracted Ion Chromatograms (EIC) of few selected peptides detected by LC–
ed from control cells. The arrow indicates the signal at m/z = 677.8087, which is relative
obtained from eIF3j that was immunoprecipitated from cells treatedwith CX-4945. In this
= 677.8087, which conﬁrms the sequence of the tryptic phosphopeptide LQEEpSDLELAK.
Fig. 3. Effect of CK2 inhibition on its interactionwith eIF3j. (A,B,C, left panels) HEK293 cells
were treated with vehicle (DMSO), 2.5 μM CX-4945 or 5 μM quinalizarin (Q1) for 5 h and
lysed. (A) Cellular lysates were analyzed by western blot with the indicated antibodies.
(B,C) Cellular lysates were immunoprecipitated with (B) pre-immune serum (Ctrl) or
anti-CK2α antibody, and (C) with anti-Fyn antibody of the same class or anti-eIF3j
antibody. Immunocomplexes were then analyzed by western blot with the indicated
antibodies. (A,B,C, right panels) Panels report the densitometric values + SD relative to
the phosphorylation extent of Akt1 phospho-Ser129 (A) and to the amount of the co-
immunoprecipitated eIF3j (B) or CK2α (C). Values are expressed as percentage relative
to the densitometric value of the bands observed in cells treated with vehicle. *p b 0.05.
Figures are representative of at least four independent experiments.
Fig. 4. Effect of CK2 inhibition by CX-4945 on eIF3j interaction with the eIF3 complex in
HEK293 cells. (A,B) HEK293 cells were treated with vehicle (Ctrl) (A) or 3 μM CX-4945
for 5 h (B). Cellswere lysed and lysate proteinswere separated on glycerol gradients as de-
tailed in Section 2.7. The following molecular weight standards were run on separate
tubes:β-amylase (200 kDa), apoferritin (443 kDa) and thyroglobulin (669kDa). Gradients
were fractionated into 19 fractions. 40 μl of the indicated fractionswas loaded on the same
gel, subjected to SDS-PAGE and analyzed bywestern blot. (C) Fractions 2 and 3 of the gra-
dients relative to untreated (Ctrl) or CX-4945-treated cells were pooled and
immunoprecipitated with anti-rpS6 antibody. Immunocomplexes were analyzed by
western blot. (D) Fractions 7 and 8, or 12 and 13 of the gradients relative to untreated
(Ctrl) or CX-4945-treated cells were pooled and immunoprecipitatedwith anti-eIF3j anti-
body. Immunocomplexes were analyzed by western blot. Figure is representative of ﬁve
independent experiments.
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co-immunoprecipitated eIF3b and eiF3d are unchanged (Fig. 3C).
To assess whether eIF3j is bound directly to CK2α and/or CK2β, pre-
liminary experiments were performed by down-regulating separately
the amount of these two CK2 subunits in HEK293 cells by RNA-
interference experiments. Cellular protein-level of CK2α and CK2β
was reduced of about 48% and 43%, respectively (Fig. S1A of Supplemen-
tary Material). Co-immunoprecipitation of the individual CK2 subunits
was then quantiﬁed in eIF3j-immunoprecipitates obtained from
the lysates of the differently treated cells. Supplementary Material
Fig. S1B shows that, in comparison with control cells, the eIF3j-
immunoprecipitates obtained from CK2α-downregulated cells contain
the expected decreased level of CK2α and a similar amount of CK2β.On the contrary, CK2β-downregulation causes a substantial reduction
of eIF3j interaction with both CK2 subunits, suggesting that the regula-
tory β-subunit might play a role as a linker between eIF3j and the CK2
catalytic α-subunit.
3.4. CK2-phosphorylation of j-subunit promotes its interaction with eIF3
complex
To get further insight into the interaction occurring between CK2
and eIF3j, HEK293 cells, treated with vehicle or CX-4945, were ﬁrst
lysed and subjected to sucrose gradient centrifugation in the presence
of MgCl2 as described elsewhere [2,8]. Under these conditions, most
eIF3j is detectable in the low-density fractions, dissociated from the
eIF3 complex (unpublished data and Ref. [2]). To recover the j-subunit
included in the eIF3 complex, cells were therefore lysed and loaded on
glycerol gradients as detailed in Section 2.7. In control cells, a part of
Fig. 5. Effect of CK2 inhibition by CX-4945 on eIF3j interaction with the eIF3 complex in
LAMA84 cells. (A,B) LAMA84 cells, treated with vehicle (DMSO) or 3 μM CX-4945 for 5 h
were lysed. Cellular lysates were immunoprecipitated with anti-CK2α (A) or anti-eIF3j
(B) and analyzed by western blot. Means of the densitometric values + SD relative to the
amount of eIF3j (A) or CK2α (B) are reported and expressed in arbitrary units. *p b 0.05 vs
the protein amount detected in cells treated with DMSO. (C,D) LAMA84 cells, treated with
vehicle (Ctrl) (C) or 3 μMCX-4945 for 5 h (D)were lysed and cellular lysates were analyzed
by glycerol gradients as detailed in the legend of Fig. 4. Gradient fractions 1–9 and 10–18
were loaded on two different gels, and analyzed bywestern blot under the same conditions.
Figure is representative of three independent experiments.
1698 C. Borgo et al. / Biochimica et Biophysica Acta 1853 (2015) 1693–1701the eIF3 complex appears in the high-density fractions of the gradient,
bound to the 40S ribosomal subunit as indicated by the co-
sedimentation and the co-immunoprecipitation of the S6 ribosomal
protein (rpS6) with the eIF3 subunits b, c, d and j (fractions 1–4 of
Fig. 4A, and Ctrl of Fig. 4C, respectively). Most of the complex is detect-
able in the gradient fractions containing protein complex(es) displaying
a molecular weight higher than 400 kDa (Fig. 4A, fractions 6–9). The
distribution of CK2α and CK2β subunits shows that only a small amount
of the protein kinase co-migrateswith the eIF3 complex in fractions 7–9
(Fig. 4A), while the majority of CK2 participates in complex(es)
displaying a lower molecular weight (fractions 10–13). Notably, cell
treatment with the CK2 inhibitor CX-4945 induces the dissociation of
a large amount of j-subunit from the eIF3 complex both bound or
unbound to the 40S subunits (Fig. 4B) and its shift toward the low-
density region of the gradient, where CK2α and CK2β are also detect-
able (fractions 11–14). The ﬁnding that cell treatment with CX-4945
does not affect the protein-level of CK2 (Fig. 3A) suggests that eIF3j
migration is induced only by inhibition of the kinase activity.
The effect of cell treatment with CX-4945 was further elucidated by
immunoprecipitating speciﬁc fractions of the gradients. Immunoprecip-
itation of rpS6 from the high-density region of the gradient (fractions 2
and 3) (Fig. 4C) demonstrates that CK2-inhibition triggers the detach-
ment of eIF3j from the protein-complex containing the other eIF3
subunits and the 40S ribosomal subunit. Immunoprecipitation of eIF3j
(Fig. 4D) supports the previous ﬁnding that cell treatment with CX-
4945 induces an increased interaction of eIF3j with inactive CK2
(Fig. 3). This is evident for both the populations of eIF3j, the one
bound to the eIF3 complex (Fig. 4D, fractions 7,8) and that migrated
to the low-density region of the gradient (fractions 12,13). The outcome
that CK2 inactivation correlates with the j-subunit dissociation from the
eIF3 complex supports the view that the CK2-phosphorylation of eIF3j is
a prerequisite for the binding of this subunit to eIF3 complex.
Considering the importance of cell translational activity in cancer,
the interplay occurring between CK2 and eIF3j was further analyzed
also in LAMA84, a chronic myeloid leukemia cell line presenting an
aberrant protein synthesis [29]. Fig. 1A demonstrates that eIF3j is an
interactor and an in vitro substrate of CK2 also in LAMA84 cells. More-
over, as previously shown in HEK293 cells (Fig. 3), treatment of these
leukemic cells with CX-4945 causes an enhanced interaction of eIF3j
with CK2. In comparison with control cells, CK2-inhibition in LAMA84
cells correlates with a strong increase of the co-immunoprecipitated
amount of eIF3j (Fig. 5A) or CK2α and CK2β (Fig. 5B) detectable in
CK2α- or eIF3j-immunoprecipitates, respectively. Glycerol gradients of
LAMA84 cellular lysates were then performed. Differently from what
were found in HEK293 cells (Fig. 4A), in control LAMA84 cells
(Fig. 5C) the eIF3 complex appears in the high-density fractions (1–8)
of the gradient andmost of it co-sediments with the 40S ribosomal sub-
units, indicating the assembly of the preinitiation complex (fractions 1–
4). A substantial amount of eIF3j is also present in the low-density
portion of the gradient (fractions 10–14), where CK2α and CK2β are
also detectable. Consistent with the results obtained with HEK293
cells, treatment of LAMA84 cells with CX-4945 (Fig. 5D) correlates
with the dissociation of a substantial amount of eIF3j from the
preinitiation complex and its migration to the low-density fractions
11–15, which contain also the protein kinase CK2.
The role played by CK2 in promoting the interaction of eIF3jwith the
other eIF3 subunits was also conﬁrmed by knocking down CK2α ex-
pression in HEK293 cells by RNA interference experiments. A decrease
of more than 40% of both CK2α protein-level and activity was observed
following CK2α silencing (Fig. 6A and B, respectively). Glycerol gradi-
ents of cell lysates demonstrate that cells transfected with non-
speciﬁc siRNA (Ctrl) exhibit a sedimentation proﬁle similar to that of
untreated cells (compare Figs. 6C and 4A). In contrast, CK2α down-
regulation induces the dissociation of an aliquot of j-subunit from eIF3
complex (Fig. 6D) conﬁrming the outcome observed by inhibiting CK2
activity with CX-4945 (Fig. 4B).3.5. S127A mutation of eIF3j affects the subunit interaction with eIF3
complex and impairs the protein synthesis
To further analyze the role played by eIF3j Ser127, HEK293 cells
were transfected with MYC-tagged cDNA of either wild type eIF3j or
the mutated counterpart containing Ser127 replaced by Ala. Fig. 7A
shows that transfected cells overexpress the same amount of Myc-
tagged proteins without affecting the expression of endogenous eIF3
subunits b and d. To reinforce the concept that Ser127 is indeed a CK2
target, wild type and mutant eIF3j were immunoprecipitated by anti-
Myc antibody and the immunocomplexes were added to a phosphory-
lation medium containing recombinant CK2. The ﬁnding that S127A-
eIF3j mutant is only slightly 33P-phosphorylated by the kinase in
comparison with the wild type subunit proves that Ser127 is the main
site of CK2-phosphorylation (Fig. 7B).
We then analyzed the interaction occurring between overexpressed
j-subunit and endogenous eIF3 subunits by immunoprecipitating
wild type or mutant Myc-eIF3j with anti-Myc antibody (Fig. 7C).
S127A mutation induces a substantial decrease of eIF3b, eIF3c
and eIF3d binding to mutated eIF3j in comparison with the interac-
tion detectable with wild type eIF3j, conﬁrming the role played
by Ser127 in eIF3j binding to the eIF3 complex. Consistently, the
parallel eIF3b-immunoprecipitation (Fig. 7D) shows a similar co-
immunoprecipitation of eIF3c and eIF3d in the two differently
transfected cells, while the binding of the Myc-tagged proteins is
different, being the amount of coimmunoprecipitated S127A-eIF3j
lower than that of wild type eIF3j.
Fig. 6. Effect of CK2α silencing on eIF3j interaction with the eIF3 complex. HEK293 cells
were transfected with non-speciﬁc siRNA (Ctrl) (A,B,C), or CK2α-speciﬁc siRNA (A,B,D)
for 72 h and lysed as described for glycerol gradients. (A) 10 μg of lysate proteins was an-
alyzed by western blot. (B) 1 μg of lysate proteins was tested for CK2 activity toward the
speciﬁc peptide RRRADDSDDDDD. *p b 0.05 vs Ctrl. (C,D) Lysate proteins were separated
on glycerol gradients and the indicated fractionswere loadedon the same gel, subjected to
SDS-PAGE and analyzed by western blot. Panels are representative of at least three sepa-
rate experiments.
Fig. 7. Effect of eIF3j S127A mutation on the eIF3j interaction with the eIF3 complex and
the overall translation efﬁciency. (A–D) HEK293 cells were transfected with wild type
(WT) or S127A-mutated Myc-eIF3j cDNA for 96 h and then lysed. (A) 20 μg of lysate pro-
teins were analyzed by western blot. (B) Lysate proteins were immunoprecipitated with
anti-Myc antibody and the immunocomplexes were 33P-phosphorylated in a phosphory-
lation medium containing 30 ng of recombinant CK2. Samples were loaded on SDS-PAGE
and blotted. Membranes were analyzed by western blot (upper panel) and by a Cyclone
Storage Phosphor-Screen to visualize 33P-radiolabeled Myc-eIF3j (lower panel). (C,D)
Lysate proteins were immunoprecipitated with either anti-Myc (C) or anti-eIF3b
(D) antibodies and analyzed by western blot. Means of the densitometric values + SD
relative to the co-immunoprecipitated bands of eIF3b (C) or Myc (D) are reported and
expressed in arbitrary units. *p b 0.05 vs the protein amount found in cells transfected
with WT Myc-eIF3j. (E) HEK293 cells, transfected with empty vector (Ctrl) or with wild
type (WT) or S127A-mutated Myc-eIF3j cDNA for 96 h, were treated with cycloheximide
and pulsed in the presence of [35S]-L-Met/Cys Protein Labeling mix as described in
Section 2.11. Cells were lysed and radioactive proteins were subjected to SDS-PAGE and
blotted. Membranes were analyzed by western blot (upper panel) and by Cyclone Plus
Storage PhosphorSystem (bar graph) to quantify the metabolic labeling, which is
expressed as percentage relative to control cells. Data representmean values± SDobtain-
ed from four independent experiments. *p b 0.05 vs the labeling detected in cells
transfected with WT Myc-eIF3j.
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has been demonstrated to cause a signiﬁcant decrease of the yeast
growth rate [10,30],while the knockingdownof eIF3j by siRNA inmam-
malian cells was found less effective on translational rate and cellular
growth [2]. We wanted to assess whether the efﬁciency of the protein
synthesis was affected by eIF3j S127A mutation. HEK293 cells,
transfected with empty vector or overexpressing a similar amount of
wild type or mutated Myc-eIF3j (Fig. 7E, upper panel), were pulsed in
the presence of a radiolabeled methionine and cysteine mix before
quantiﬁcation of total protein labeling. Fig. 7E (bar graph) shows that
the overall protein synthesis of control cells (Ctrl) is not affected by
the overexpression of wild type Myc-eIF3j (WT). Notably, expression
of S127A-eIFj mutant is accompanied by more than 30% reduction of
the translation efﬁciency in comparison with cells transfected with
wild type eIF3j, demonstrating that eIF3j Ser127 plays a regulatory
role in the translational control of protein synthesis.
4. Discussion
In this study we demonstrate by means of both immunoprecipita-
tion experiments and mass spectrometry analyses that eIF3 complex
is associated with CK2 in human cells and that eIF3j subunit is a new
substrate of this protein kinase (Fig. 1). Although two eIF3 polypeptides
isolated from rabbit reticulocytes and displaying the molecular weights
of 70,000 and 120,000, have been described as theﬁrst CK2 substrates in
very early studies [31,32], no other evidence has been subsequently
provided that human eIF3 is regulated by CK2. It has been reported
that eIF3c is a substrate of CK2 in plants [33] and that the yeasthomologues of eIF3b and eIF3c are phosphorylated by CK2 [34]. Here
we demonstrate that CK2 phosphorylates the eIF3 j-subunit at Ser127,
a residue located in the sequence LQEEpSDLELAK matching the CK2
phosphorylation consensus sequence. This is speciﬁed by a carboxylic
or pre-phosphorylated amino acid at position n + 3 with respect to
the target residue and optimized by additional acidic amino acids in
the proximity of the phosphorylatable residue [16,27]. Phospho-
proteomic studies have already demonstrated that eIF3 Ser127 is
phosphorylated in cells [35–38]. Our results show that this residue is
speciﬁcally phosphorylated by CK2 since the eIF3j Ser127 phosphoryla-
tion does not occur in cells treated with the CK2-inhibitor CX-4945
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Ser127 is replaced by Ala (Fig. 7B). Phospho-proteomic analyses have
also shown that, like eIF3j, other mammalian eIF3 subunits contain
phospho-residues located in sequences potentially susceptible to
phosphorylation by CK2 [35,37], suggesting a global role of CK2 in the
regulation of eIF3, a central player in the mechanism of translational
control, whose alterations may lead to either cell malignancy or cell
death [39,40]. With regard to this, the notion that CK2 is abnormally
elevated in a wide variety of tumors, where it is exploited as an anti-
apoptotic and pro-survival agent, suggests that the oncogenic potential
of this protein kinase might also rely on its ability to functionally affect
eIF3, whose contribution to oncogenesis and maintenance of the
malignant phenotype has been amply demonstrated [41–43].
Cell treatment with CK2 inhibitors demonstrates that, once the ki-
nase activity is inhibited, CK2 greatly enhances its binding to j-subunit
(Figs. 3 and 5). Notably, this binding increase is partially due to a sub-
population of j-subunitmolecules that dissociate from eIF3 complex fol-
lowing CK2 inhibition and co-migrate with inactive CK2 as demonstrat-
ed by differential sedimentation in glycerol gradients obtained with
HEK293 and chronic myeloid leukemic LAMA84 cells (Figs. 4 and 5).
The ﬁnding that treatment of LAMA84 cells with CX-4945 induces the
detachment of eIF3j from the preinitiation complex suggests that this
event is involved in the decreased viability caused in these leukemic
cells by CX-4945-inhibition of CK2 activity [44]. Consistently, the
down-regulation of cellular CK2 by knocking-down the CK2α catalytic
subunit in HEK293 cells by siRNA induces a similar dissociation of
j-subunit from eIF3 complex (Fig. 6C and D). These results are in agree-
ment with studies showing that eIF3j is a loosely associated subunit,
easily detachable from the rest of the eIF3 complex during puriﬁcation
and detectable in cells also as unbound protein [9,12]. The ﬁnding that
CK2 inhibition promotes both the dissociation of j-subunit from eIF3
and its increased binding to the kinase suggests that: i) non-
phosphorylated eIF3j binds to CK2 more than its phosphorylated
counterpart; ii) eIF3j, once phosphorylated by CK2, dissociates from
the kinase; iii) eIF3j dissociation from the eIF3 complex is likely caused
by the reduced CK2 activity and not by the decreased protein-level of
the kinase (Fig. 6) as demonstrated in cells treated with CX-4945
(Figs. 4 and 5), that contain an unchanged amount of CK2 (Fig. 3A).
This hypothesis is also supported by the reduced interaction of
j-subunit with the eIF3 complex occurring when active CK2 is unable
to phosphorylate eIF3j due to Ser127Ala mutation (Fig. 7); iv) CK2-
phosphorylation of eIF3j triggers the interaction of this subunit with
the other complex subunits, an event that has been described to play a
stabilizing role in forming the eIF3 complex [9,10,13] as well as in the
eIF3 binding with the decoding center of the 40S ribosomal subunits
[8,9,11–13]. It has been also recently shown that eIF3j and eIF3 complex
bind cooperatively to the 40S ribosomal subunit and that thewhole eIF3
complex is critical for the high afﬁnity binding of eIF3j on the 43S
preinitiation complex [13].
In mammals, the recruitment and positioning of Met-tRNAi on the
small 40S ribosomal subunit to form the 43S preinitiation complex are
mediated and stabilized by the eukariotic initiation factors eIF1, eIF1A,
eIF2, eIF3 and eIF5 [45,46]. It has been demonstrated that CK2 interacts
with and phosphorylates human eIF2β and eIF5 affecting the translation
initiation complex formation and the cellular growth rate [47,48]. Our
results showing that also eIF3j is phosphorylated by CK2 reveal that
most of the initiation factors acting inmammalianpreinitiation complex
are regulated by CK2.
The key role played by eIF3j Ser127 in eIF3 complex assembly and
translation initiationmachinery is further supported by the data obtain-
ed upon transfection of HEK293 cells with a plasmid encoding S127A-
eIF3j mutant. We found that the amount of endogenous eIF3 subunits
interacting with S127A-eIF3j is much lower than that detected in cells
overexpressing wild type eIF3j (Fig. 7C and D). Our results also show
that protein synthesis is markedly reduced in cells containing S127A-
eIF3j mutant in comparison with cells overexpressing wild type eIF3j(Fig. 7E), consistent with the notion that the main mechanism regulat-
ing the overall rate of protein synthesis involves the phosphorylation of
the initiation factors [39].
Collectively taken, our data demonstrate that CK2 phosphorylation
of eIF3j at Ser127 regulates the j-subunit association with eIF3 complex
and underscore the crucial role of CK2 in the initiation of protein
synthesis.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2015.04.004.
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